Eloxx reports Q4 net loss $6.3M, cash $19.2M; Phase 2 Alport study ongoing, IND filed for ZKN-013

Eloxx Pharmaceuticals, Inc.

2023-Q1 EPS reported -$2.88 vs consensus -$2.60 ▼ miss (-10.7%)

Net loss $6.3M ($2.92/share) vs $12.1M loss in Q4 2021; R&D and G&A expenses decreased YoY.
Unrestricted cash $19.2M at Dec 31, 2022; amended Hercules loan repaid $7.5M; cash runway into Q3 2023.
Three patients dosed in Phase 2 ELX-02 for Alport; initial proteinuria reduction observed; topline data H1 2023.
IND filed for ZKN-013 for RDEB; preclinical read-through up to 18-fold increase in COL VII protein.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Eloxx Pharmaceuticals, Inc. reported the three months ended December 31, 2022 results: net income net loss of $6.3 million, EPS $2.92 per share.

Period: the three months ended December 31, 2022
Net income: net loss of $6.3 million
EPS: $2.92 per share
Result: reported results

Exact text from the filing

For the three months ended December 31, 2022, we incurred a net loss of $6.3 million, or $2.92 per share

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Eloxx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-040585

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.